Sun's plan for rest of Taro rejected amid hopes of sweetened offer
This article was originally published in Scrip
Executive Summary
Taro Pharmaceutical Industries has rejected Sun Pharmaceutical Industries' offer to acquire the remaining 34% of Taro it does not already own, saying that the proposal is not in the best interest of the Israeli firm's minority shareholders, leading some analysts to believe that a sweetened offer is inevitable.